Investing.com - Regeneron Pharma (NASDAQ:REGN) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $15.37 on revenue of $3.45B. Analysts polled by Investing.com anticipated EPS of $10.17 on revenue of $2.72B.
Regeneron Pharma shares are down 3% from the beginning of the year, still down 5.03% from its 52 week high of $686.62 set on September 3. They are under-performing the S&P 500 which is up 24.08% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on October 27 with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.38B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar